The caging group as a transient active-site inhibitor canbe subsequently removed using light-induced deprotection, thus providinga means to gain precise insights into the effects of cancer-associatedmutations in TET2 on the catalytic kinetics of TET2 in vivo. The gene discussed is TET2; the disease is cancer.